BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260701T093000
DTEND;TZID=Europe/Brussels:20260701T133000
DTSTAMP:20260726T050954
CREATED:20260505T073147Z
LAST-MODIFIED:20260519T114509Z
UID:9589-1782898200-1782912600@www.europabio.org
SUMMARY:EuropaBio Biomanufacturing Policy Summit 2026
DESCRIPTION:From legislation to impact for Europe \n\n\n\nBiomanufacturing lies at the heart of Europe’s future societal and entrepreneurial strength and is changing the business landscape for both emerging innovators and established industry champions. \n\n\n\nEuropaBio’s 4th Biomanufacturing Policy Summit will focus on how legislation delivers impact within a proactive Biomanufacturing strategy\, and how we establish EU targets for outcomes. It will also showcase the 2026 update of the EuropaBio WIfoR study ‘Measuring the Economic Footprint of the Biotechnology Industry in the European Union’ prior to full report launch in September. \n\n\n\nThe prize is globally competitive multi-sector biomanufacturing\, keeping pace with industrial transition in major global regions and securing Europe’s supply chains\, healthcare future\, decarbonisation and economic resilience. \n\n\n\nThis meeting will bring together EuropaBio Members\, representatives of key sectors\, plus national and EU stakeholders across institutions. \n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/05/Event-Banner-EuropaBio-Biomanufacturing-Policy-Summit-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260414T143000
DTEND;TZID=Europe/Brussels:20260414T153000
DTSTAMP:20260726T050954
CREATED:20260309T135321Z
LAST-MODIFIED:20260309T143349Z
UID:9503-1776177000-1776180600@www.europabio.org
SUMMARY:The EU Biotech Act: Europe’s ambition for biotechnology
DESCRIPTION:Join Director General Sandra Gallina and EuropaBio to explore the EU Biotech Act proposal\, published in December 2025. \n\n\n\nThe webinar explores the Goal of the Act\, to boost innovation\, support development of biotech products and accelerate time-to-market\, making use of industrial enablers and regulatory simplification. \n\n\n\nThis webinar will introduce the drivers behind the Biotech Act proposal plus its diverse and ambitious mechanisms to boost EU biotech delivery. It will discuss how mechanisms might work and the interlink of the Act with the wider European Legislative landscape\, and its legislative pathway into action for the EU. \n\n\n\nWebinar delegates will have the opportunity to ask Director General Gallina questions during the event and EuropaBio will publish a summary for all participants. \n\n\n\nAGENDA \n\n\n\n\n\n\n\n\n14h30: Introduction – Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n\n\n\n\n\n\n14h40: The Biotech Act in focus – Director General Sandra Gallina\, DG Health and Food Safety\, European Commission: \n\n\n\n\n\nRegulatory streamlining and facilitation in health\, food and other biotech\n\n\n\nIndustrial enablers including High Impact Strategic Projects\, Boosting innovative biotech & biosimilars\, Access to Finance\, AI and Data\, Biosecurity & Defence\n\n\n\n\n15h10: Discussion and audience Q&A \n\n\n\n15h30: Close \n\n\n\nWho should attend? If you are active within biotechnology in any sector\, you should attend to understand what the Act means for you\, how you should be involved and what happens next. \n\n\n\nRegister below \n\n\n\n\nRegistration Here
URL:https://www.europabio.org/event/the-eu-biotech-act-europes-ambition-for-biotechnology/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/03/Event-Banners-Website-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T163000
DTEND;TZID=Europe/Brussels:20260323T180000
DTSTAMP:20260726T050954
CREATED:20260317T081056Z
LAST-MODIFIED:20260317T081058Z
UID:9523-1774283400-1774288800@www.europabio.org
SUMMARY:Special feature: Biotech Act Part I – Dr Claire Skentelbery\, Director General EuropaBio @ BIO-Europe Spring 2026
DESCRIPTION:Join our Director General Dr Claire Skentelbery at BIO-Europe Spring on the 23rd of March for an afternoon session dedicated to the EU Biotech Act Part 1. \n\n\n\nThe EU Biotech Act represents a landmark piece of legislation aimed at positioning Europe as a global leader in biotech. Structured in two parts\, the legislative program seeks to drive competitiveness across multiple sectors. Part I of the EU Biotech Act\, published in December 2025\, focuses on advancing health innovation. Key initiatives include accelerating clinical trials\, extending intellectual property protections\, launching a robust investment program\, and introducing strategic projects designed to achieve critical mass in applied innovation. Part II\, set to be unveiled in 2026\, will shift the focus toward maximising biomanufacturing across industries\, further strengthening Europe’s biotech ecosystem. \n\n\n\nThis feature session is dedicated to the Biotech Act part\, including a Keynote and Fireside Chat. \n\n\n\n16:30 Keynote presentation: Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n17:00 Fireside chat: Dr Claire Skentelbery in discussion with Dr Tilo Mandry\, Lead International Liaison Manager IGES \n\n\n\n17:15: Session: Special feature: Biotech Act Part I – What’s in it for me? Industry panel discussionPanelists:– Dr Morgane Rousselot\, Founder\, Chairwoman and CEO\, SeaBeLife Biotech– Dr Ann Belien\, Founder & CEO\, Rejuvenate Biomed (tbc)– Andreas Prenner\, Policy Officer\, European Commission– Dr Marjo Puumalainen\, International Director\, SwedenBIO– Dr Tilo Mandry\, Lead International Liaison Manager\, IGES (Moderator) \n\n\n\nThis panel continues the EU Biotech Act Special Feature: We will discuss what the Biotech Act means for biotech companies and Europe as a biotech investment location\, and how companies can best adapt to its provisions. \n\n\n\nThere are many questions about the Biotech Act:– How will industrial clinical research be accelerated and how will this affect the development of innovative therapies?– How will the Biotech Act impact the financing of innovative biotech start-ups?– Can cell and gene therapies now be developed more quickly by companies in the EU and brought to patients more easily?– What does the extension of intellectual property protection mean for biopharmaceutical companies in practice?– Is the Act sufficiently targeted at industry and where are the risk points?– And finally\, can the EU compete globally\, particularly with the US and China\, thanks to the Biotech Act?We will discuss these and many other important aspects with the panelists and the audience. \n\n\n\n18:00: Close \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/special-feature-biotech-act-part-i-dr-claire-skentelbery-director-general-europabio-bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T080000
DTEND;TZID=Europe/Brussels:20260325T200000
DTSTAMP:20260726T050954
CREATED:20260219T090517Z
LAST-MODIFIED:20260219T090524Z
UID:9470-1774252800-1774468800@www.europabio.org
SUMMARY:BIO-Europe Spring 2026
DESCRIPTION:EuropaBio is joining BIO-Europe Spring 2026. \n\n\n\nBIO-Europe Spring is Europe’s largest springtime biotech partnering event\, bringing together over 3\,700 leaders and innovators in the life sciences industry. It’s designed for partnering\, business development\, and licensing opportunities in biotechnology and pharmaceuticals. \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20251015T120000
DTEND;TZID=Europe/Brussels:20251015T210000
DTSTAMP:20260726T050954
CREATED:20250505T110759Z
LAST-MODIFIED:20250814T132321Z
UID:9042-1760529600-1760562000@www.europabio.org
SUMMARY:Biotech & Biomanufacturing Policy Summit
DESCRIPTION:EuropaBio is pleased to host its third Summit focused on biotechnology & biomanufacturing. \n\n\n\nBiotechnology is a critical technology for Europe.  Delivery of innovation into market drives competitiveness\, security\, supply chain resilience plus societal and environmental goals.  Europe must be ambitious and globally aware\, with a focus on securing its biotechnology capability within fast changing global geopolitics. \n\n\n\nThe current Commission has a significant opportunity to set and deliver on the ambition needed. Legislation such as the Biotech Act\, plus the frameworks that we create for sectors including health\, agri-food and manufacturing. \n\n\n\nThe half day Summit brings together EuropaBio Members and stakeholders to understand the ambition needed for legislation\, how the EU and its Member States can deliver and recognition of global positioning needed. \n\n\n\nIt is supported by biotech product displays and EU projects\, plus evening networking reception. It will be followed by a Summit Statement and public webinar hosted in November. \n\n\n\nAgenda: \n\n\n\n12:30 Registration and lunch13:15 Welcome and Keynote session Summit keynotes bring Industry\, Parliament and Commission perspectives to Europe’s ambition for biotech and biomanufacturing and the policy framework currently in action. Commissioner Olivér Várhelyi – Commissioner for Health and Animal Welfare Markus Staempfli – EuropaBio Chair\, Vice President Europe Major Markets & Canada\, CSL Behring MEP Stine Bosse – MEP and co-chair EU Alliance of Biotech and Life Sciences14:00 Panel sessions The current legislative cluster impacting biotechnology and biomanufacturing is in focus for our panel discussions. Stakeholders from across industry\, policy and member states discuss what Europe’s ambition must be and how individual and aligned legislations can deliver.Panel 1 – Enabling EU markets How policy creates markets for biotech products and enables biomanufacturing processes.Panel 2 – Enhancing access How market pathways are vital for product and process commercial viability\, determining speed and scale of access and uptake.Panel 3 – Building the EU ecosystem How knowledge\, skills\, finance and infrastructure deliver on market potential for Europe.17:50 Pre-reception remarks18:00 Reception20:30 Close\n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/biotech-biomanufacturing-policy-summit/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/05/Event-Banner-Website-Biotech-Biomanufacturing-Policy-Summit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250507T000000
DTEND;TZID=Europe/Brussels:20250508T235959
DTSTAMP:20260726T050954
CREATED:20250303T145152Z
LAST-MODIFIED:20250303T145236Z
UID:8834-1746576000-1746748799@www.europabio.org
SUMMARY:Knowledge for Growth 2025
DESCRIPTION:Mark your calendar for Knowledge for Growth 2025\, Europe’s premier life sciences conference\, taking place on 8 May 2025 in the dynamic city of Antwerp\, Belgium! \n\n\n\nConnect with over 1\,000 life sciences professionals from 500+ companies and organisations\, including decision-makers from biotech\, pharma\, MedTech\, AgTech\, and healthtech\, as well as investors\, universities\, research institutes\, policymakers\, and service providers. \n\n\n\nImmerse yourself in an action-packed programme offering exclusive insights into the global and regional life sciences landscape\, one-to-one partnering\, a vibrant trade fair\, and countless networking opportunities. \n\n\n\nDon’t miss the chance to elevate your knowledge and expand your network at Knowledge for Growth 2025! \n\n\n\nUSE CODE: KFG2025CLUSTER15 FOR A 15% DISCOUNT \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/knowledge-for-growth-2025/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/03/Event-Banners-Website-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250129T183000
DTEND;TZID=Europe/Brussels:20250129T203000
DTSTAMP:20260726T050954
CREATED:20241217T125548Z
LAST-MODIFIED:20250128T102313Z
UID:8543-1738175400-1738182600@www.europabio.org
SUMMARY:A Driver of European Competitiveness: The Future of European Biotech
DESCRIPTION:EuropaBio\, the European association representing Bioindustries\, will host an evening reception co-hosted by MEP Stine Bosse (Vice-Chair\, SANT) and MEP Eszter Lakos (Member\, ITRE)\, to discuss the role of the European biotech sector in making the European industry more competitive. \n\n\n\nAmbassador Søren Jacobsen\, Deputy Permanent Representative of Denmark to the EU\, and Kristin Schreiber\, Director at DG GROW\, Klaus Berend\, Director SANTE will share some remarks on their approach to the biotech sector in the new mandate. \n\n\n\nThis event is only open to EuropaBio members & invited guests\, to find out more about EuropaBio membership\, contact us through our website here.
URL:https://www.europabio.org/event/a-driver-of-european-competitiveness-the-future-of-european-biotech/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/12/EUROPABIO.6788f179502696.54888785.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241225T080000
DTEND;TZID=Europe/Brussels:20241227T200000
DTSTAMP:20260726T050954
CREATED:20241113T103614Z
LAST-MODIFIED:20241113T103616Z
UID:8467-1735113600-1735329600@www.europabio.org
SUMMARY:2nd ESAB Digital Congress
DESCRIPTION:After the successful first digital ESAB Congress last year\, the Scientific Committee has decided that a digital ESAB congress will take place again this year from November 25-27. \n\n\n\nDeadline for abstract submission: 31 October 2024 \n\n\n\nESAB Aims \n\n\n\n\nto take initiatives in areas of growing scientific and industrial interest and importance in the field of applied biocatalysis\n\n\n\n\n\nto identify key topics which may be rate-limiting in the development of scientific progress and technological prospects in applied biocatalysis and to take steps to stimulate these areas\n\n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/2nd-esab-digital-congress/
CATEGORIES:Biomanufacturing Platform,External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/11/Event-Banner-E-Congress-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241008T100000
DTEND;TZID=Europe/Brussels:20241010T180000
DTSTAMP:20260726T050954
CREATED:20240828T135105Z
LAST-MODIFIED:20240828T135930Z
UID:8158-1728381600-1728583200@www.europabio.org
SUMMARY:CPHI Milan
DESCRIPTION:EuropaBio is pleased to partner with CPHI Milan 2024\, the biggest international pharmaceutical industry event for the thirty fifth anniversary edition. This year’s edition held from the 8th to the 10th of October in Fiera Milano\, Italy promises to a packed agenda with over 150 expert international speakers with over 100 content sessions. \n\n\n\nJoin our Director General Dr Claire Skentelbery this year where she will be speaking on the 9th of October to discuss how cultivated meat has the potential to revolutionise biologic manufacturing. Join her in Hall 3 – 3F97 at 16:15 on 09/10/2024 to find out more. \n\n\n\n \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/cphi-milan/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/CPHI-x-EuropaBio-2024-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240710T080000
DTEND;TZID=Europe/Brussels:20240711T170000
DTSTAMP:20260726T050954
CREATED:20240531T135225Z
LAST-MODIFIED:20240531T135227Z
UID:7893-1720598400-1720717200@www.europabio.org
SUMMARY:CURIOUS­ FUTURE INSIGHT™ CONFERENCE
DESCRIPTION:Over the millennia science & technology have steadily advanced\, but key unsolved challenges remain\, and much more is possible. The Curious – Future Insight™ Conference brings together some of the world’s brightest scientists and most accomplished innovators to present their work and explore the future of science and technology\, solving the challenges of today and enabling the dreams of a better tomorrow. \n\n\n\nThe Curious – Future Insight™ conference featurestop speakers and Nobel laureates from all over theworld\, among them: \n\n\n\n\nEmmanuelle Charpentier\, MPI (2018)\n\n\n\nSteven Chu\, Stanford University (2024)\n\n\n\nRobert Langer\, MIT (2024)\n\n\n\nSatya Nadella\, CEO Microsoft (2018)\n\n\n\nUğur Şahin\, CEO BioNTech (2024)\n\n\n\nRandy Schekman\, Berkeley (2024)\n\n\n\nThomas C. Südhof\, Stanford University (2024\, 2022)\n\n\n\nCraig Venter\, Craig Venter Institute (2018)
URL:https://www.europabio.org/event/curious-future-insight-conference/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Curious-Insights-Banner-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240507T140000
DTEND;TZID=Europe/Brussels:20240507T150000
DTSTAMP:20260726T050954
CREATED:20240429T082059Z
LAST-MODIFIED:20240429T084605Z
UID:7736-1715090400-1715094000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit - Report Launch
DESCRIPTION:“Policy pathways for biomanufacturing in Europe” was the theme of the Biomanufacturing Policy Summit 2024. The upcoming report will summarise the Summit’s keynote speeches and panel discussions and translate them into an analysis to Europe’s biomanufacturing strengths\, weaknesses\, opportunities and threats based on specific policies and industrial examples. \n\n\n\nThe report launch will also feature speakers who will respond to the report’s main conclusions and comment on their alignment with current challenges and future goals. \n\n\n\n\nHanna Freienstein\, Policy Officer\, DG GROW – European Commission\n\n\n\n⁠Jérôme Fabiano\, Deputy Director & Corporate Affairs Director\, EIT Health France\n\n\n\n⁠Per Falholt\, Chief Science Officer\, 21st.BIO\n\n\n\n\nThe boost to biotech and biomanufacturing needs a strong knowledge-based approach and the upcoming report aims to contribute to the discussion. Do not miss the opportunity and be up to date about biomanufacturing in Europe.
URL:https://www.europabio.org/event/europabios-biomanufacturing-policy-summit-report-launch/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-600-x-200-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240313T130000
DTEND;TZID=Europe/Brussels:20240313T200000
DTSTAMP:20260726T050954
CREATED:20231213T100000Z
LAST-MODIFIED:20240209T113124Z
UID:7082-1710334800-1710360000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe
DESCRIPTION:The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers\, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative\, regulatory and strategic pathways. \n\n\n\n2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative\, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum\, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries. \n\n\n\n \n\n\n\n13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe\, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception \n\n\n\n \n\n\n\nParticipants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative\, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness\, Green Transition and resilience across sectors. \n\n\n\nFor all enquiries\, please contact our Biomanufacturing Platform Coordinator\, Francisco Castro Alves: f.alves@europabio.org
URL:https://www.europabio.org/event/biomanufacturing-policy-summit-2024-policy-pathways-for-biomanufacturing-in-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Event-Banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230427T140000
DTEND;TZID=Europe/Brussels:20230427T151500
DTSTAMP:20260726T050954
CREATED:20230322T114230Z
LAST-MODIFIED:20230412T135959Z
UID:6092-1682604000-1682608500@www.europabio.org
SUMMARY:EuropaBio Biomanufacturing Policy Summit 2023: Where next for Europe?
DESCRIPTION:Summit outcomes and next steps \n\n\n\n\n\nOn 15th March\, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels\, with the aim of setting the vision for Europe’s global innovation\, competitiveness\, and sustainability on biomanufacturing\, while raising awareness among policy-makers. The Summit established a starting point\, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs\, large companies\, expert services\, and EU institutions – and which has already started in other parts of the world. \n\n\n\n80 attendees from industry\, national associations\, and stakeholders across the public and private spectrum presented\, debated\, and proposed.  In a fast-moving industrial transition\, calls for visionary policies\, enabling regulation\, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here. \n\n\n\nWould you like to find out more? \n\n\n\nJoin us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions. \n\n\n\nBiomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing! \n\n\n\nAGENDA\n\n\n\n14:00: Welcome and introduction – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio\, Sr Adviser & Programme Manager\, EuropaBio \n\n\n\nThe report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe. \n\n\n\n14:20: Report perspectives & reflections from healthcare and biotech industries\, and national associations – Sarah Moundir\, EU Public Affairs Senior Manager\, Novartis | Gwenael Servant\, Board Executive\, Abolis | Inga Matijosyte\, Vice President\, LithuaniaBIO \n\n\n\nA diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes\, as well as the priorities for their companies and organisations. \n\n\n\n14:50: Discussion and Q&A with the audience \n\n\n\nA discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing. \n\n\n\n15:10: Close – Closing remarks. \n\n\n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2023-where-next-for-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/SM1-Quotes-Key-Messages-600-×-200px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230315T130000
DTEND;TZID=Europe/Brussels:20230315T190000
DTSTAMP:20260726T050954
CREATED:20221114T094047Z
LAST-MODIFIED:20230308T114450Z
UID:5505-1678885200-1678906800@www.europabio.org
SUMMARY:Biomanufacturing Platform - Policy Summit 2023
DESCRIPTION:EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation\, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy. \n\n\n\nThe half day meeting will bring together Members and invited stakeholders from across the policy\, finance\, trade\, skills and regulatory spectrum surrounding biomanufacturing. \n\n\n\nDiscussion will address what biomanufacturing looks like across sectors and the roles played by SMEs\, large companies and expert services. The economic and skills footprint will be reviewed\, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally\, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action. \n\n\n\nFrom the first Summit\, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform. \n\n\n\nAgenda \n\n\n\n14:00Opening plenary14:00Welcome and introduction to the Biomanufacturing Policy Summit– Claire Skentelbery\, Director General\, EuropaBio14:10Biomanufacturing in Europe’s industrial transition– Peter Dröll\, Director Prosperity\, European Commission\, DG Research and Innovation14:30Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus– Hilary Stiss\, Director\, International Affairs\, Biotechnology Innovation Organization (BIO) 14:45Quo vadis European Biomanufacturing innovation in a competitive\, globalized world– Wojciech Nowak\, Global Senior Director\, Novartis15:00I am Biomanufacturing: examples in action        ● Resilience\, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick\, Senior Vice President Research\, Development and Innovation (RDI)\, Nutrition & Care (NC-RDI)\, Evonik Operations GmbH       ● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk\, Founder and Chief Science Officer\, SwiftPharma       ● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland\, Deputy Secretary General Bio.be       ● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen\, VP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics15:30Break16:00Parallel Breakout discussionsBreakout 1 – Advanced healthcare: Role and growth in Europe● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning\, delivering\, investment● Patient access to advanced therapies (including rare diseases).● Competitiveness and economic contributor across EuropeBreakout 2 – Resilience\, competitiveness and sustainability:● Transition of industrial process for sustainability●  Building resilience of supply● Innovation for competitiveness17:10Closing plenaryClosing panel discussion: Europe’s ambition and pathway for biomanufacturingStakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve\, the pathway towards those goals and how it can make use of the skills\, infrastructure and policy/regulatory frameworks through which Europe develops.Moderator: Kristin Schreiber (Director DG GROW)Panelists: Peter Wehrheim (Head of Unit RTD.B2)\, Kristin Thompson (COO EUREKARE)\, Nessa Fennelly (Senior Executive IBEC)\, Nicolo Giacomuzzi-Moore (Executive Director CBE JU)\, Stefaan Fiers (Head of Corporate Communication\, Public Affairs and Patient Advocacy Takeda Belgium).18:00Networking reception19:00Close\n\n\n\n \n\n\n\nSpeakers \n\n\n\n\n\n\n\n\n\n\nHilary Stiss\n\n\n\nDirector\, International Affairs\, BIO Program Director\, ICBA \n\n\n\nAs a Director for International Affairs at the Biotechnology Innovation Organization (BIO)\, Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe\, the Middle East\, North Africa\, Turkey and South Africa regions. In this position\, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA). \n\n\n\n\n\n\n\n\n\n\n\n\n\nClaire Skentelbery\n\n\n\nClaire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions\, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network\, working across sectors\, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017\, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Ute Schick\n\n\n\nSenior Vice President Research\, Development and Innovation\, Evonik \n\n\n\nDr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food\, Health\, Cosmetic Industry and Material Science. Before her current role with Evonik\, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM. \n\n\n\n\n\n\n\n\n\n\n\n\n\nWojciech Nowak\n\n\n\nGroup Senior Director\, Global Governmental and Public Affairs\, Novartis International\, Switzerland.(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe\, Central Asia). \n\n\n\nMulticultural\, inclusive and reflective leader who lived in 6 countries on 3 continents.Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems\, EU integration and global pharmaceutical market. \n\n\n\nStarted his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters\, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris\, France) and Health Directorate of the European Commission (DG SANCO\, Luxembourg). \n\n\n\nAfter joining private sector has been serving in a number of senior leadership roles of growingresponsibility in healthcare companies(GlaxoSmithKline\, Abbott\, Novartis) on country\, regional and global levels (Poland\, Belgium\, Switzerland). \n\n\n\nEducated in Poland\, United States\, Nederlands\, Switzerland\, with the background in political sciences\, international relations (Warsaw’s University\, Poland; European Institute of Public Administration\, Maastricht\, Nederlands) and business administration (IMD Business School Lausanne\, Switzerland) he is an expert in healthcare systems\, global healthcare policies and international business. \n\n\n\nPassionate about delivering access and best healthcare outcomes to patients around the World. \n\n\n\n\n\n\n\n\n\n\n\n\n\nTineke Van Hooland\n\n\n\nDeputy Secretary general of bio.be/essenscia  \n\n\n\nTineke Van Hooland is Deputy Secretary general of bio.be/essenscia\, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio\, the European Association for Bioindustries\, from which she also chairs the NAC\, National Associations Council. Prior to this\, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs\, Market Access\, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003. \n\n\n\nTineke is also the founder and CEO of epic 10\, a boutique external affairs consultancy firm\, and a respected board member in various other organizations.  She is known for her dynamic and no-nonsense approach\, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Schreiber\n\n\n\nKristin Schreiber leads the Directorate Ecosystems I: Chemicals\, Food\, Retail\, Health in DG GROW\, the Directorate General for Internal Market\, Industry\, Entrepreneurship and SMEs. \n\n\n\nPrior to her current Director position\, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021). \n\n\n\nKristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla\, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition. \n\n\n\n\n\n\n\n\n\n\n\n\n\nStefaan Fiers\n\n\n\nCorporate Communications\, Public Affairs and Patient Advocacy Takeda \n\n\n\nStefaan is Head of Corporate Communications\, Public Affairs and Patient Advocacy at Takeda Belgium\, one of the largest pharmaceutical companies in Belgium. With his team\, he secures the healthcare policy analysis\, engages with external stakeholders and coordinates the company’s communication strategy. Additionally\, he oversees Takeda’s public affairs activities in 24 mid-sized European countries. \n\n\n\nBefore joining Takeda in June 2020\, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry\, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.Next to his activities at Takeda\, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven\, a Board member of PACE (Public Affairs Community Europe)\, and the author of several books and peer-reviewed articles. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPhilippe Moyen\n\n\n\nVP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics \n\n\n\nFollowing a university focus on therapeutic systems\, followed by formulation and industrial development\, Philippe has worked across the biotechnology spectrum including Baxter Healthcare\, Fresenius Kabi\, Stallergenes Greer\, and PTC Therapeutics where he has a strong focus on operations. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Thompson\n\n\n\nVP\, Chief Business Officer \n\n\n\nKristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that\, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina\, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm\, Germany. \n\n\n\n\n\n\n\n\n\n\n\n\n\nNicoló Giacomuzzi-Moore\n\n\n\nExecutive Director ad interim\, Circular Bio-based Industries Joint Undertaking \n\n\n\nNicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years\, focusing on research and innovation policy\, program implementation\, and enterprise support. \n\n\n\nBefore joining BBI JU (now CBE JU) in 2016\, he worked for the European Commission’s Research Executive Agency\, where he was responsible for financial and legal support in implementing European research projects. \n\n\n\nNicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Dröll\n\n\n\nDirector for Prosperity\, Directorate-General for Research and Innovation \n\n\n\nPeter Dröll has been working in the European Commission for more than 20 years with positions in the environment\, enlargement negotiations\, industry policy\, innovation\, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik. \n\n\n\nSince 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability\, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies. \n\n\n\nBefore joining the European Commission in 1991\, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJeroen Hofenk\n\n\n\nFounder and Chief Science Officer\, SwiftPharma \n\n\n\nJeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-\, animal cell-based\, and plants.  In the last 10 years of his career\, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.” \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Wehrheim\n\n\n\nHead of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels \n\n\n\nWhile working for Phil Hogan\, Commissioner for Agriculture and Rural Development\, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE\, Maryland/US (with a Heisenberg scholarship from the German Research Foundation)\, and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen\, Germany \n\n\n\n\n\n\nAbout the EuropaBio Biomanufacturing Platform \n\n\n\nThe Platform has the mission to represent biomanufacturing at the highest policy levels in Europe\, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions. \n\n\n\nEuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered.  Together with members and stakeholders\, it will address how economic growth\, employment and resilience are achieved through policy\, legal frameworks and regulation at EU and national levels. \n\n\n\nThe Summit will be open to EuropaBio Members and invited stakeholders. Please contact c.skentelbery@europabio.org for further information.
URL:https://www.europabio.org/event/biomanufacturing-platform-policy-summit-2023/
LOCATION:BIP Meeting Center – House of the Capital Region\, rue Royale 2-4\, Brussels\, 1000\, Belgium
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/SM1-Quotes-Key-Messages-600-×-200px.png
END:VEVENT
END:VCALENDAR